![]() |
Volumn 395, Issue 10223, 2020, Pages e30-e31
|
Erratum: Department of Error (The Lancet (2020) 395(10223) (e30–e31), (S0140673620303044), (10.1016/S0140-6736(20)30304-4));Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BARICITINIB;
AZETIDINE DERIVATIVE;
SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2;
SULFONAMIDE;
BINDING AFFINITY;
CORONAVIRINAE;
CORONAVIRUS DISEASE 2019;
CORONAVIRUS INFECTION;
DRUG BLOOD LEVEL;
DRUG INHIBITION;
HUMAN;
LETTER;
PREDICTION;
PRIORITY JOURNAL;
SCORING SYSTEM;
SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2;
VIRUS ENTRY;
VIRUS GENOME;
BETACORONAVIRUS;
AZETIDINES;
BETACORONAVIRUS;
HUMANS;
SULFONAMIDES;
|
EID: 85079122891
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(20)31376-3 Document Type: Erratum |
Times cited : (1169)
|
References (7)
|